CG Oncology reported $984.5M in cash and updated business milestones for 2026. The company expects to achieve key interim data in its pivotal trials and total $984.5M in cash sufficient to fund operations through 2029.
CG Oncology reported $984.5M in cash and updated business milestones for 2026. The company expects to achieve key interim data in its pivotal trials and total $984.5M in cash sufficient to fund operations through 2029.